Clinical Trials

NCT Number: NCT05799248 Phase: PHASE3 Trial Summary: Study Title: Role of rhPSMA-7.3 PET/CT imaging in men with High-Risk prostate cancer following conventional imaging and associated changes in medical management Protocol number: BED-IIT-437 Phase: 3b – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): MidLantic Urology Acronym:

NCT Number: NCT05939414 Phase: PHASE3 Trial Summary: The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after defini – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Novartis Pharmaceuticals Acronym: PSMA-DC

NCT Number: NCT05125016 Phase: Phase 1|Phase 2 Trial Summary: To assess the safety, tolerability, and pharmacokinetics (PK) and to determine recommended phase 2 dosing regimen (RP2DR) of REGN4336 separately as monotherapy or in combination wi – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Regeneron Pharmaceuticals Acronym:

NCT Number: NCT04729114 Phase: Phase 1|Phase 2 Trial Summary: A Phase 1/2a, open-label, multicenter study of intramuscular (i.m.) PRL-02 depot in participants with advanced prostate cance – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Astellas Pharma Global Development, Inc. Acronym:

NCT Number: NCT04471727 Phase: Phase 1|Phase 2 Trial Summary: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab i – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, […]

NCT Number: NCT04557449 Phase: PHASE1|PHASE2 Trial Summary: This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Pfizer Acronym: CDK4i

NCT Number: NCT06378866 Phase: PHASE2 Trial Summary: This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Mayo Clinic Acronym: DIVINE

NCT Number: NCT06150417 Phase: PHASE2 Trial Summary: The purpose of this study is to find out if giving radiation therapy (RT) to areas of metastatic prostate cancer at the time a participant is diagnosed will help control disease better than the usual – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Case Comprehensive Cancer […]

NCT Number: NCT06312670 Phase: PHASE2 Trial Summary: The purpose of this study is to study the effects of EPI-7386 in combination with Enzalutamide on participants diagnosed with prostate cancer. The main goals of this study are to evaluate the antitumo – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Pedro Barata, MD, MSc Acronym:

NCT Number: NCT06395753 Phase: PHASE2 Trial Summary: The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Debiopharm International SA Acronym: